iCAD (ICAD) – FDA
-
iCAD (ICAD) Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
-
iCAD (ICAD) Granted Clearance from FDA for ProFound AI Version 3.0 for 3D Mammography
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ICAD Stock Lookup